[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100600883":3},{"organization":4,"outcomesModule":7,"designInfo":17,"detailedDescription":16,"studyPopulation":16,"armGroups":23,"interventions":35,"overallOfficials":16,"centralContacts":16,"locations":16,"responsibleParty":45,"collaborators":16,"id":47,"slug":16,"hasResults":48,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":16,"eligibilityCriteria":52,"healthyVolunteers":53,"sex":54,"minAge":55,"maxAge":16,"enrollmentInfo":56,"targetDuration":16,"studyType":59,"phases":60,"briefSummary":62,"conditions":63,"keywords":16,"overallStatus":65,"whyStopped":16,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":16},{"fullName":5,"class":6},"Addpharma Inc.","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":16,"otherOutcomes":16},[9,13],{"measure":10,"description":11,"timeFrame":12},"Area under the plasma concentration-time curve during dosing interval (AUCt)","AUCt of AD-116","pre-dose (0hour) to 72hours",{"measure":14,"description":15,"timeFrame":12},"Maximum concentration of drug in plasma (Cmax)","Cmax of AD-116",null,{"allocation":18,"interventionModel":19,"interventionModelDescription":16,"primaryPurpose":20,"observationalModel":16,"timePerspective":16,"maskingInfo":21},"RANDOMIZED","CROSSOVER","TREATMENT",{"masking":22,"maskingDescription":16,"whoMasked":16},"NONE",[24,31],{"label":25,"type":26,"description":27,"interventionNames":28},"Sequence A","EXPERIMENTAL","Period 1 : Reference Drug(AD-1161), Period 2 : Test Drug(AD-116)",[29,30],"Drug: AD-116","Drug: AD-1161",{"label":32,"type":26,"description":33,"interventionNames":34},"Sequence B","Period 1 : Test Drug(AD-116), Period 2 : Reference Drug(AD-1161)",[29,30],[36,41],{"type":37,"name":38,"description":39,"armGroupLabels":40,"otherNames":16},"DRUG","AD-116","AD-116 Oral Tablet",[25,32],{"type":37,"name":42,"description":43,"armGroupLabels":44,"otherNames":16},"AD-1161","AD-1161 Oral Capsule",[25,32],{"type":46,"investigatorFullName":16,"investigatorTitle":16,"investigatorAffiliation":16,"oldNameTitle":16,"oldOrganization":16},"SPONSOR","100600883",false,"NCT07103278","A Clinical Trial to Evaluate the Safety and the Pharmacokinetics of AD-116 Compared to AD-1161 in Healthy Adult Male Volunteers","An Open-label, Randomized, Single-dose, 2-sequence, 2-period, Crossover Study to Evaluate the Safety and the Pharmacokinetics of AD-116 Compared to AD-1161 in Healthy Adult Male Volunteers Under Fasting Conditions","Inclusion Criteria:\n\n* Body weight equal to or greater than 50kg and Body mass index (BMI) between 18.0 kg\u002Fm2 and 30.0 kg\u002Fm2 at the time of screening visit\n* The Age equal to or greater than 19 in healthy adult male volunteers at the time of screening visit\n\nExclusion Criteria:\n\n* Participation in another clinical study with an investigational drug within the 6 months from scheduled first administration\n* Other exclusions applied",true,"MALE","19 Years",{"count":57,"type":58},44,"ESTIMATED","INTERVENTIONAL",[61],"PHASE1","The study compare and evaluate the safety and pharmacokinetic characteristics between the administration of AD-116 and the administration of AD-1161 in healthy adult male volunteers",[64],"Benign Prostatic Hyperplasia","NOT_YET_RECRUITING","2025-09-30",{"date":68,"type":69},"2025-10-03","ACTUAL",{"date":71,"type":58},"2025-12",{"date":73,"type":58},"2026-01",{"name":5,"class":6}]